Aptorum Group
APMAPM · Stock Price
Historical price data
Overview
Aptorum Group is a clinical-stage biotech with a mission to facilitate life science innovations that tackle unmet medical needs, particularly in oncology and infectious diseases. Its strategy combines internal discovery platforms, including computational and AI-enhanced methods for drug repurposing and novel target identification, with the acquisition of external clinical-stage assets to build its portfolio. The company's primary achievements include advancing its lead candidates, ALS-4 for MRSA and NCL-195 for neuroblastoma, through preclinical development while maintaining a lean operational structure. Its outlook hinges on successfully transitioning these assets into clinical trials to generate human proof-of-concept data.
Technology Platform
Aptorum employs computational/AI-enhanced discovery and a dedicated drug repurposing platform to identify novel candidates and new uses for existing molecules, aiming to accelerate and de-risk early-stage development.
Pipeline
2| Drug | Indication | Stage | Watch |
|---|---|---|---|
| ALS-4 + Placebo + ALS-4 + ALS-4 + Placebo | Healthy Subject | Phase 1 | |
| SACT-1 + EDURANT 25Mg Tablet | Healthy Subject | Phase 1 |
Opportunities
Risk Factors
Competitive Landscape
Aptorum competes in the anti-MRSA space against large pharma and specialized biotechs with newer antibiotics, and in neuroblastoma against targeted therapy and immunotherapy developers. Its micro-cap size is a significant disadvantage, necessitating that its candidates demonstrate clear differentiation to secure a niche.
